Blogs
Beaufond PLC registers 62.16 % increase in EBITDA to USD 17.736 million of against USD 10.937 million to the corresponding period of last year.
Beaufond PLC continues to pursue its development strategy and once again delivers strong operating results, outperforming its industry. Beaufond PLC’s pharmaceutical business has recorded an excellent performance in 2020, exhibiting once again the relevance of its strategy and its operational discipline. Quarter after quarter, Beaufond PLC demonstrates its ability to Read more…